Recolony takes home CHF 150’000 winning the third stage of the Venture Kick competition

22-02-2023 – Recolony wins the third stage of the Venture Kick competition. The startup will use the funds to advance its cancer immunotherapy, aiming to regenerate the intestinal microbiota of cancer patients to trigger a potent anti-tumor immune response.


The funding from Venture Kick will enable Recolony to advance its small molecule program towards the pre-clinical phase to provide cancer patients with a novel, more effective, safer therapeutic solution.  In 2025, the biotech startup plans to perform the first-in-human clinical trials with CRC patients at the University Hospital of Zurich. The additional capital comes after the startup received Innobooster financial support.